Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BerGenBio ASA
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Females of non-childbearing potential at the time of provision of informed consent
Ability to understand and provide written confirmation of informed consent after reading study information, discussion with the investigator, and adequate time to decide on participation
Consents to storage of study-related samples and data for exploratory use
Histologically confirmed HGSOC
Platinum-resistant relapsed disease; defined as progressive disease based on imaging within \<= 6 months from completion of most recent regimen
You may not be if
Primary platinum-refractory disease (ie, progression during the first platinum regimen or within 4 weeks of completion of the first platinum regimen) with rapid progression and life-threatening disease manifestation
Life expectancy \< 6 months
Concurrent anticancer therapy
Participants who are breastfeeding
Known uncontrolled central nervous system metastases. Participants without known brain metastases do not require radiological imaging prior to enrolment
